- Home
- ALTS vs IMAB Comparison
ALTS vs IMAB Comparison
Compare ALTS & IMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALTS
- IMAB
- Stock Information
- Founded
- ALTS 1976
- IMAB 2014
- Country
- ALTS United States
- IMAB United States
- Employees
- ALTS N/A
- IMAB N/A
- Industry
- ALTS
- IMAB Biotechnology: Pharmaceutical Preparations
- Sector
- ALTS
- IMAB Health Care
- Exchange
- ALTS NYSE
- IMAB Nasdaq
- Market Cap
- ALTS 72.7M
- IMAB 79.9M
- IPO Year
- ALTS N/A
- IMAB 2020
- Fundamental
- Price
- ALTS $4.78
- IMAB $0.82
- Analyst Decision
- ALTS
- IMAB Strong Buy
- Analyst Count
- ALTS 0
- IMAB 3
- Target Price
- ALTS N/A
- IMAB $8.00
- AVG Volume (30 Days)
- ALTS 211.9K
- IMAB 234.1K
- Earning Date
- ALTS 05-02-2025
- IMAB 03-21-2025
- Dividend Yield
- ALTS N/A
- IMAB N/A
- EPS Growth
- ALTS N/A
- IMAB N/A
- EPS
- ALTS N/A
- IMAB N/A
- Revenue
- ALTS $7,110,000.00
- IMAB $569,464.00
- Revenue This Year
- ALTS N/A
- IMAB N/A
- Revenue Next Year
- ALTS N/A
- IMAB N/A
- P/E Ratio
- ALTS N/A
- IMAB N/A
- Revenue Growth
- ALTS N/A
- IMAB N/A
- 52 Week Low
- ALTS $1.29
- IMAB $0.76
- 52 Week High
- ALTS $7.75
- IMAB $2.00
- Technical
- Relative Strength Index (RSI)
- ALTS 37.29
- IMAB 31.17
- Support Level
- ALTS $4.41
- IMAB $0.76
- Resistance Level
- ALTS $5.66
- IMAB $0.93
- Average True Range (ATR)
- ALTS 0.50
- IMAB 0.07
- MACD
- ALTS -0.22
- IMAB -0.01
- Stochastic Oscillator
- ALTS 8.03
- IMAB 18.03
About ALTS ALT5 SIGMA CORPORATION
ALT5 Sigma Corp is a fintech company. It is providing next generation blockchain-powered technologies for tokenization, trading, clearing, settlement, payment and safe-keeping of digital assets. The company product include ALT 5 Prime is an electronic over-the-counter trading platform and ALT 5 Pay crypto payment processor.
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).